Last $53.37 USD
Change Today +2.25 / 4.40%
Volume 1.3M
ASPX On Other Exchanges
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

auspex pharmaceuticals inc (ASPX) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/19/14 - $54.30
52 Week Low
02/5/14 - $13.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

auspex pharmaceuticals inc (ASPX) Related Businessweek News

No Related Businessweek News Found

auspex pharmaceuticals inc (ASPX) Details

Auspex Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing novel medicines for the treatment of orphan diseases. The company’s product candidates are used to address medical needs primarily in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications. Its lead product candidate includes SD-809 that is in Phase 3 registration clinical trial for the treatment of chorea associated with Huntington’s disease. The company’s other product candidates comprise SD-254, deuterium-containing form of venlafaxine, which has completed two Phase 1 clinical trial, as well as preclinical stage of development products include SD-560, a deuterium-containing form of pirfenidone; SD-970, a deuterium-containing form of tofacitinib, and a deuterium-containing form of ketamine. Auspex Pharmaceuticals, Inc. was founded in 2001 and is based in San Diego, California.

33 Employees
Last Reported Date: 11/10/14
Founded in 2001

auspex pharmaceuticals inc (ASPX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.5K
Chief Medical Officer
Total Annual Compensation: $291.2K
Vice President of Research
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2013.

auspex pharmaceuticals inc (ASPX) Key Developments

Auspex Pharmaceuticals, Inc. - Special Call

To discuss top line efficacy and safety results from its Phase 3 registration trial evaluating SD-809 for the treatment of chorea associated with Huntington's disease

Auspex Pharmaceuticals, Inc. Announces Positive Results from Registration Trial of SD-809 for Chorea Associated with Huntington's Disease

Auspex Pharmaceuticals, Inc. announced that it dedicated to developing innovative medicines for people with movement disorders and other rare diseases, announced positive efficacy and safety results from its Phase 3 registration trial evaluating SD-809 for the treatment of chorea associated with Huntington's disease (HD), called First-HD. In addition to meeting the primary efficacy endpoint, significant improvements in both patient and clinical global impressions of change and quality of life were observed. Importantly, the study showed a favorable safety and tolerability profile, including low rates of depression, somnolence, akathisia/restlessness and anxiety. In addition, Auspex announced results from an analysis of the completed four-week Switch portion of the ARC-HD study, which also has an ongoing long-term safety component. Data from the study show that patients who switched from the current standard of care, tetrabenazine, to SD-809 maintained chorea control at both week one and week four. Huntington's disease is a genetic disorder that causes a wide variety of symptoms including involuntary movements, problems with emotion, behavior, thinking, processing information, and ultimately leads to death. Approximately 90% of patients with Huntington's disease will develop chorea, which is characterized by involuntary, excessive movements that can impact all parts of the body and interferes with motor functions. As a result, chorea associated with Huntington's disease can be severely debilitating. First-HD was a 1:1 randomized, double-blind, placebo-controlled, parallel-group trial evaluating the efficacy, safety and tolerability of SD-809 in the management of chorea associated with Huntington's disease. The primary efficacy endpoint for the study was the change from baseline to maintenance therapy in the Total Maximal Chorea (TMC) score of the Unified Huntington's Disease Rating Scale (UHDRS). There were four pre-specified key secondary endpoints that were tested on a hierarchical basis: treatment success based on patient global impression of change (PGIC) and clinical global impression of change (CGIC), quality of life and balance. Other pre-specified motor endpoints were also analyzed. A total of 90 patients (45 in each group) were enrolled for evaluation over 13 weeks: patients were titrated weekly to an optimal dose up to week eight; were on maintenance therapy for four weeks, and; were taken off study medication in the final week of the study. A total of 87 patients completed the study; one patient in the SD-809 group and two in the placebo group discontinued. SD-809 met the pre-specified primary efficacy endpoint. In parallel to First-HD, Auspex completed the four-week Switch portion of the ARC-HD study, which has an ongoing long-term safety component. Although designed primarily as a safety study, maintenance of chorea control was assessed after switching patients overnight from tetrabenazine to SD-809 (at approximately half the dose of tetrabenazine). All available data through eight weeks following the switch were included in the analysis. After switching from tetrabenazine to SD-809, chorea was assessed at one and four weeks. Dose adjustments were permitted after week one. The mean total chorea score decreased by approximately one point from baseline on the TMC score.

Auspex Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 09:50 AM

Auspex Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 09:50 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Pratik Shah, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASPX:US $53.37 USD +2.25

ASPX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ASPX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ASPX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUSPEX PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at